Related Experiment Video
Updated: Aug 19, 2026

Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
[Antipyrine metabolism in lung cancer patients]
E Radzikowska1, W Gaździk, E Rowińska-Zakrzewska
1III Kliniki Gruźlicy i Chorób Płuc Instytutu Gruźlicy i Chorób Płuc, Warszawie.
Abstract:
In order to assess the activity of enzymatic metabolism of oncogenic benzo (a) pyrenes the half life of antipyrine was calculated in 60 lung cancer patients and 75 healthy volunteers without known familial malignancy. It was found that antipyrine activity was significantly higher in lung cancer patients than in healthy volunteers, after taking in account sex, age and smoking habits. Antipyrine half life was significantly higher in adenocarcinoma in comparison with other types of cancer. Metabolism of antipyrine was also higher in advanced cases of lung cancer. A relation between higher metabolism and lower age onset of lung cancer was not demonstrated.
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase